| 发明名称 | Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon | ||
| 摘要 | The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate. | ||
| 申请公布号 | US9034837(B2) | 申请公布日期 | 2015.05.19 |
| 申请号 | US201012767631 | 申请日期 | 2010.04.26 |
| 申请人 | Roche Innovation Center Copenhagen A/S | 发明人 | Hildebrandt-Eriksen Elisabeth S.;Petri Andreas;Kauppinen Sakari;Abrahamsen Niels;Lanford Robert Eldon |
| 分类号 | A61K48/00;C07H21/02;C07H21/04;A61K31/7105;C12N15/113 | 主分类号 | A61K48/00 |
| 代理机构 | Sterne, Kessler, Goldstein & Fox P.L.L.C. | 代理人 | Sterne, Kessler, Goldstein & Fox P.L.L.C. |
| 主权项 | 1. A method of treating a hepatitis C virus (HCV)-infected subject who responds poorly to interferon therapy comprising administering an effective amount of an anti-miR-122 oligonucleotide to the subject, wherein (a) the anti-miR-122 oligonucleotide has a length of 7 to 18 nucleotides; (b) the anti-miR-122 oligonucleotide comprises least one LNA nucleotide analogue; (c) the anti-miR-122 oligonucleotide comprises least one phosphorothioate internucleotide linkage; and, (d) the anti-miR-122 oligonucleotide is essentially incapable of recruiting RNase H. | ||
| 地址 | Hørsholm DE | ||